Shandong Lukang Pharmaceutical (SHA:600789) received marketing application approval from China's National Medical Products Administration for brexpiprazole as an active pharmaceutical ingredient, according to a Thursday filing with the Shanghai bourse.
The ingredient is an antipsychotic that helps balance dopamine and serotonin, according to the filing.
Lukang has so far invested nearly 4.8 million yuan in research and development of the drug, it said.
Shares rose 2% during afternoon trading on Thursday.